CR20190542A - Compuestos - Google Patents
CompuestosInfo
- Publication number
- CR20190542A CR20190542A CR20190542A CR20190542A CR20190542A CR 20190542 A CR20190542 A CR 20190542A CR 20190542 A CR20190542 A CR 20190542A CR 20190542 A CR20190542 A CR 20190542A CR 20190542 A CR20190542 A CR 20190542A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- tmlrcs
- tmlr
- lrcs
- manufacture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención proporciona compuestos que son inhibidores alostéricos selectivos de mutantes de receptor del factor de crecimiento epidérmico (RFCE) que contienen TMLR, TMLCRS, LR, LRCS, su preparación, composiciones farmacéuticas que los contienen y su utilización como sustancias terapéuticamente activas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514244P | 2017-06-02 | 2017-06-02 | |
| EP17174334 | 2017-06-02 | ||
| US201762543438P | 2017-08-10 | 2017-08-10 | |
| PCT/EP2018/064399 WO2018220149A1 (en) | 2017-06-02 | 2018-06-01 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190542A true CR20190542A (es) | 2020-01-14 |
Family
ID=62495802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190542A CR20190542A (es) | 2017-06-02 | 2018-06-01 | Compuestos |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11117890B2 (es) |
| EP (1) | EP3630754B8 (es) |
| JP (1) | JP7191045B2 (es) |
| KR (1) | KR20200015595A (es) |
| CN (1) | CN110753691B (es) |
| AU (1) | AU2018276441B2 (es) |
| BR (1) | BR112019025370A2 (es) |
| CA (1) | CA3065874A1 (es) |
| CL (1) | CL2019003501A1 (es) |
| CO (1) | CO2019013557A2 (es) |
| CR (1) | CR20190542A (es) |
| ES (1) | ES2927480T3 (es) |
| IL (1) | IL271013B2 (es) |
| MA (1) | MA48946A (es) |
| MX (1) | MX390898B (es) |
| MY (1) | MY201976A (es) |
| PE (1) | PE20200718A1 (es) |
| PH (1) | PH12019502662A1 (es) |
| PL (1) | PL3630754T3 (es) |
| TW (1) | TWI774780B (es) |
| UA (1) | UA126452C2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA129328C2 (uk) | 2019-06-21 | 2025-03-19 | Ф. Хоффманн-Ля Рош Аг | Інгібітор egfr для лікування раку |
| JP2023551769A (ja) | 2020-12-01 | 2023-12-13 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規インダゾール誘導体 |
| CN118525018A (zh) * | 2021-12-21 | 2024-08-20 | 上海艾力斯医药科技股份有限公司 | 一种联炔类化合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008332B2 (en) | 2006-05-31 | 2011-08-30 | Takeda San Diego, Inc. | Substituted indazoles as glucokinase activators |
| EP2148944A1 (en) * | 2007-05-25 | 2010-02-03 | Burnham Institute for Medical Research | Inhibitors of thapsigargin-induced cell death |
| US20110212078A1 (en) * | 2008-06-25 | 2011-09-01 | Reddy Panduranga Adulla P | Synthesis and use of heterocyclic antibacterial agents |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| CN102060848B (zh) | 2010-12-09 | 2013-09-18 | 天津药物研究院 | 芳香胺取代的嘧啶衍生物的制备及用途 |
| CN102093339B (zh) | 2010-12-09 | 2013-06-12 | 天津药物研究院 | 一类嘧啶衍生物的制备及用途 |
| WO2013170770A1 (zh) * | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | 具有抗肿瘤活性的乙炔衍生物 |
| TW201607930A (zh) * | 2014-07-18 | 2016-03-01 | 百濟神州有限公司 | 作為ｔ７９０ｍ／ｗｔ－ｅｇｆｒ的選擇性和不可逆的激酶抑制劑的５－氨基－４－氨甲醯基－吡唑化合物及其用途 |
| RU2702631C2 (ru) * | 2014-10-11 | 2019-10-09 | Шанхай Хэнсох Биомедикал Ко., Лтд. | Ингибитор egfr и его получение и применение |
| BR112017024481B1 (pt) * | 2015-05-14 | 2020-11-17 | The Wistar Institute Of Anatomy And Biology | composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo |
| CA2987914C (en) * | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| TW201834651A (zh) | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
-
2018
- 2018-06-01 CR CR20190542A patent/CR20190542A/es unknown
- 2018-06-01 MA MA048946A patent/MA48946A/fr unknown
- 2018-06-01 CN CN201880036589.7A patent/CN110753691B/zh active Active
- 2018-06-01 PL PL18728875.8T patent/PL3630754T3/pl unknown
- 2018-06-01 AU AU2018276441A patent/AU2018276441B2/en not_active Ceased
- 2018-06-01 TW TW107118846A patent/TWI774780B/zh not_active IP Right Cessation
- 2018-06-01 PE PE2019002464A patent/PE20200718A1/es unknown
- 2018-06-01 JP JP2019566634A patent/JP7191045B2/ja active Active
- 2018-06-01 CA CA3065874A patent/CA3065874A1/en active Pending
- 2018-06-01 ES ES18728875T patent/ES2927480T3/es active Active
- 2018-06-01 KR KR1020197038496A patent/KR20200015595A/ko not_active Ceased
- 2018-06-01 MY MYPI2019007060A patent/MY201976A/en unknown
- 2018-06-01 MX MX2019014332A patent/MX390898B/es unknown
- 2018-06-01 UA UAA202000003A patent/UA126452C2/uk unknown
- 2018-06-01 BR BR112019025370-0A patent/BR112019025370A2/pt not_active IP Right Cessation
- 2018-06-01 EP EP18728875.8A patent/EP3630754B8/en active Active
-
2019
- 2019-11-25 PH PH12019502662A patent/PH12019502662A1/en unknown
- 2019-11-28 IL IL271013A patent/IL271013B2/en unknown
- 2019-11-29 CO CONC2019/0013557A patent/CO2019013557A2/es unknown
- 2019-11-29 CL CL2019003501A patent/CL2019003501A1/es unknown
- 2019-12-02 US US16/700,900 patent/US11117890B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3630754B1 (en) | 2022-07-27 |
| US11117890B2 (en) | 2021-09-14 |
| UA126452C2 (uk) | 2022-10-05 |
| PE20200718A1 (es) | 2020-07-21 |
| CN110753691B (zh) | 2024-02-02 |
| RU2019143647A3 (es) | 2021-09-28 |
| MA48946A (fr) | 2020-04-08 |
| AU2018276441A1 (en) | 2019-12-12 |
| EP3630754B8 (en) | 2022-08-31 |
| AU2018276441B2 (en) | 2022-04-28 |
| BR112019025370A2 (pt) | 2020-06-23 |
| MX2019014332A (es) | 2022-03-24 |
| ES2927480T3 (es) | 2022-11-07 |
| CL2019003501A1 (es) | 2020-06-05 |
| IL271013B2 (en) | 2023-02-01 |
| IL271013A (en) | 2020-01-30 |
| RU2019143647A (ru) | 2021-07-09 |
| JP7191045B2 (ja) | 2022-12-16 |
| CO2019013557A2 (es) | 2020-01-17 |
| PL3630754T3 (pl) | 2022-10-24 |
| CN110753691A (zh) | 2020-02-04 |
| JP2020524659A (ja) | 2020-08-20 |
| KR20200015595A (ko) | 2020-02-12 |
| IL271013B (en) | 2022-10-01 |
| TWI774780B (zh) | 2022-08-21 |
| MX390898B (es) | 2025-03-21 |
| US20200102299A1 (en) | 2020-04-02 |
| EP3630754A1 (en) | 2020-04-08 |
| CA3065874A1 (en) | 2018-12-06 |
| MY201976A (en) | 2024-03-27 |
| PH12019502662A1 (en) | 2020-06-08 |
| TW201902892A (zh) | 2019-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020552154A1 (en) | Compounds | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| PH12022550469A1 (en) | Kras g12d inhibitors | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| SG10201810879VA (en) | Pharmaceutical compounds | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| EP4292594A3 (en) | Inhibitors of ret | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| EA201790650A1 (ru) | Лекарственная форма и способы применения абиратерона ацетата | |
| MX2020010116A (es) | Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). | |
| MX2019002057A (es) | Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. | |
| EA202091337A1 (ru) | Ингибиторы гистонацетилтрансфераз семейства myst | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| EA201890364A1 (ru) | СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t | |
| PH12019502662A1 (en) | Compounds | |
| ZA202102816B (en) | High concentration protein formulation | |
| EA202090424A1 (ru) | Бициклические ингибиторы гистондеацетилазы | |
| EA201591480A1 (ru) | Способы лечения дискинезии и сопутствующих расстройств | |
| MX2019005294A (es) | Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos. | |
| PL401632A1 (pl) | Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję | |
| EA201891680A1 (ru) | Производные индана в качестве модуляторов mglur7 |